APO Research
Talk to an analyst

APO RESEARCH · REPORT

Fabrazyme (agalsidase beta)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Fabrazyme (agalsidase beta) Market Analysis and Forecast 2026-2032

20 December 2025196 pages

Choose your research edition.

Industry ResearchFabrazyme (agalsidase beta) Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Fabrazyme (agalsidase beta) Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal Fabrazyme (agalsidase beta) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fabrazyme (agalsidase beta) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Fabrazyme (agalsidase beta) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Fabrazyme (agalsidase beta) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Fabrazyme (agalsidase beta) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Fabrazyme (agalsidase beta) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Fabrazyme (agalsidase beta) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Fabrazyme (agalsidase beta) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Fabrazyme (agalsidase beta) include Genzyme Corporation. etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Fabrazyme (agalsidase beta), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Fabrazyme (agalsidase beta), also provides the sales of main regions and countries. Of the upcoming market potential for Fabrazyme (agalsidase beta), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Fabrazyme (agalsidase beta) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Fabrazyme (agalsidase beta) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Fabrazyme (agalsidase beta) sales, projected growth trends, production technology, application and end-user industry.

Fabrazyme (agalsidase beta) Segment by Company

Genzyme Corporation

Fabrazyme (agalsidase beta) Segment by Type

5mg/vial

35mg/vial

Fabrazyme (agalsidase beta) Segment by Application

Hospital

Drug store

Fabrazyme (agalsidase beta) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fabrazyme (agalsidase beta) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fabrazyme (agalsidase beta) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fabrazyme (agalsidase beta).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Fabrazyme (agalsidase beta) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Fabrazyme (agalsidase beta) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Fabrazyme (agalsidase beta) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Fabrazyme (agalsidase beta) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 5mg/vial Major Manufacturers Table 3. 35mg/vial Major Manufacturers Table 4. Global Fabrazyme (agalsidase beta) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Drug store Major Manufacturers Table 7. Fabrazyme (agalsidase beta) Industry Trends Table 8. Fabrazyme (agalsidase beta) Industry Drivers Table 9. Fabrazyme (agalsidase beta) Industry Opportunities and Challenges Table 10. Fabrazyme (agalsidase beta) Industry Restraints Table 11. Global Fabrazyme (agalsidase beta) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Fabrazyme (agalsidase beta) Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Fabrazyme (agalsidase beta) Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Fabrazyme (agalsidase beta) Revenue Market Share by Region (2021-2026) Table 15. Global Fabrazyme (agalsidase beta) Revenue Market Share by Region (2027-2032) Table 16. Global Fabrazyme (agalsidase beta) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 17. Global Fabrazyme (agalsidase beta) Sales by Region (2021-2026) & (W Units) Table 18. Global Fabrazyme (agalsidase beta) Sales by Region (2027-2032) & (W Units) Table 19. Global Fabrazyme (agalsidase beta) Sales Market Share by Region (2021-2026) Table 20. Global Fabrazyme (agalsidase beta) Sales Market Share by Region (2027-2032) Table 21. Global Fabrazyme (agalsidase beta) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Fabrazyme (agalsidase beta) Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Fabrazyme (agalsidase beta) Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Fabrazyme (agalsidase beta) Sales Market Share by Manufacturers (2021-2026) Table 25. Global Fabrazyme (agalsidase beta) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Fabrazyme (agalsidase beta) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Fabrazyme (agalsidase beta) Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Fabrazyme (agalsidase beta) Manufacturers, Product Type & Application Table 29. Global Fabrazyme (agalsidase beta) Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Fabrazyme (agalsidase beta) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Fabrazyme (agalsidase beta) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Fabrazyme (agalsidase beta) Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Fabrazyme (agalsidase beta) Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Fabrazyme (agalsidase beta) Revenue Market Share by Type (2021-2026) Table 36. Global Fabrazyme (agalsidase beta) Revenue Market Share by Type (2027-2032) Table 37. Global Fabrazyme (agalsidase beta) Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 38. Global Fabrazyme (agalsidase beta) Sales by Type (2021-2026) & (W Units) Table 39. Global Fabrazyme (agalsidase beta) Sales by Type (2027-2032) & (W Units) Table 40. Global Fabrazyme (agalsidase beta) Sales Market Share by Type (2021-2026) Table 41. Global Fabrazyme (agalsidase beta) Sales Market Share by Type (2027-2032) Table 42. Global Fabrazyme (agalsidase beta) Price by Type (2021-2026) & (US$/Unit) Table 43. Global Fabrazyme (agalsidase beta) Price by Type (2027-2032) & (US$/Unit) Table 44. Global Fabrazyme (agalsidase beta) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Fabrazyme (agalsidase beta) Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Fabrazyme (agalsidase beta) Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Fabrazyme (agalsidase beta) Revenue Market Share by Application (2021-2026) Table 48. Global Fabrazyme (agalsidase beta) Revenue Market Share by Application (2027-2032) Table 49. Global Fabrazyme (agalsidase beta) Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 50. Global Fabrazyme (agalsidase beta) Sales by Application (2021-2026) & (W Units) Table 51. Global Fabrazyme (agalsidase beta) Sales by Application (2027-2032) & (W Units) Table 52. Global Fabrazyme (agalsidase beta) Sales Market Share by Application (2021-2026) Table 53. Global Fabrazyme (agalsidase beta) Sales Market Share by Application (2027-2032) Table 54. Global Fabrazyme (agalsidase beta) Price by Application (2021-2026) & (US$/Unit) Table 55. Global Fabrazyme (agalsidase beta) Price by Application (2027-2032) & (US$/Unit) Table 56. Genzyme Corporation Company Information Table 57. Genzyme Corporation Business Overview Table 58. Genzyme Corporation Fabrazyme (agalsidase beta) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. Genzyme Corporation Fabrazyme (agalsidase beta) Product Portfolio Table 60. Genzyme Corporation Recent Development Table 61. North America Fabrazyme (agalsidase beta) Revenue by Type (2021-2026) & (US$ Million) Table 62. North America Fabrazyme (agalsidase beta) Revenue by Type (2027-2032) & (US$ Million) Table 63. North America Fabrazyme (agalsidase beta) Sales by Type (2021-2026) & (W Units) Table 64. North America Fabrazyme (agalsidase beta) Sales by Type (2027-2032) & (W Units) Table 65. North America Fabrazyme (agalsidase beta) Sales Price by Type (2021-2026) & (US$/Unit) Table 66. North America Fabrazyme (agalsidase beta) Sales Price by Type (2027-2032) & (US$/Unit) Table 67. North America Fabrazyme (agalsidase beta) Revenue by Application (2021-2026) & (US$ Million) Table 68. North America Fabrazyme (agalsidase beta) Revenue by Application (2027-2032) & (US$ Million) Table 69. North America Fabrazyme (agalsidase beta) Sales by Application (2021-2026) & (W Units) Table 70. North America Fabrazyme (agalsidase beta) Sales by Application (2027-2032) & (W Units) Table 71. North America Fabrazyme (agalsidase beta) Sales Price by Application (2021-2026) & (US$/Unit) Table 72. North America Fabrazyme (agalsidase beta) Sales Price by Application (2027-2032) & (US$/Unit) Table 73. North America Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 74. North America Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 75. North America Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 76. North America Fabrazyme (agalsidase beta) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 77. North America Fabrazyme (agalsidase beta) Sales by Country (2021-2026) & (W Units) Table 78. North America Fabrazyme (agalsidase beta) Sales by Country (2027-2032) & (W Units) Table 79. North America Fabrazyme (agalsidase beta) Sales Price by Country (2021-2026) & (US$/Unit) Table 80. North America Fabrazyme (agalsidase beta) Sales Price by Country (2027-2032) & (US$/Unit) Table 81. United States Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 82. Canada Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 83. Europe Fabrazyme (agalsidase beta) Revenue by Type (2021-2026) & (US$ Million) Table 84. Europe Fabrazyme (agalsidase beta) Revenue by Type (2027-2032) & (US$ Million) Table 85. Europe Fabrazyme (agalsidase beta) Sales by Type (2021-2026) & (W Units) Table 86. Europe Fabrazyme (agalsidase beta) Sales by Type (2027-2032) & (W Units) Table 87. Europe Fabrazyme (agalsidase beta) Sales Price by Type (2021-2026) & (US$/Unit) Table 88. Europe Fabrazyme (agalsidase beta) Sales Price by Type (2027-2032) & (US$/Unit) Table 89. Europe Fabrazyme (agalsidase beta) Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe Fabrazyme (agalsidase beta) Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe Fabrazyme (agalsidase beta) Sales by Application (2021-2026) & (W Units) Table 92. Europe Fabrazyme (agalsidase beta) Sales by Application (2027-2032) & (W Units) Table 93. Europe Fabrazyme (agalsidase beta) Sales Price by Application (2021-2026) & (US$/Unit) Table 94. Europe Fabrazyme (agalsidase beta) Sales Price by Application (2027-2032) & (US$/Unit) Table 95. Europe Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Europe Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 97. Europe Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 98. Europe Fabrazyme (agalsidase beta) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 99. Europe Fabrazyme (agalsidase beta) Sales by Country (2021-2026) & (W Units) Table 100. Europe Fabrazyme (agalsidase beta) Sales by Country (2027-2032) & (W Units) Table 101. Europe Fabrazyme (agalsidase beta) Sales Price by Country (2021-2026) & (US$/Unit) Table 102. Europe Fabrazyme (agalsidase beta) Sales Price by Country (2027-2032) & (US$/Unit) Table 103. Germany Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 104. France Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 105. U.K. Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 106. Italy Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 107. Netherlands Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 108. China Fabrazyme (agalsidase beta) Revenue by Type (2021-2026) & (US$ Million) Table 109. China Fabrazyme (agalsidase beta) Revenue by Type (2027-2032) & (US$ Million) Table 110. China Fabrazyme (agalsidase beta) Sales by Type (2021-2026) & (W Units) Table 111. China Fabrazyme (agalsidase beta) Sales by Type (2027-2032) & (W Units) Table 112. China Fabrazyme (agalsidase beta) Sales Price by Type (2021-2026) & (US$/Unit) Table 113. China Fabrazyme (agalsidase beta) Sales Price by Type (2027-2032) & (US$/Unit) Table 114. China Fabrazyme (agalsidase beta) Revenue by Application (2021-2026) & (US$ Million) Table 115. China Fabrazyme (agalsidase beta) Revenue by Application (2027-2032) & (US$ Million) Table 116. China Fabrazyme (agalsidase beta) Sales by Application (2021-2026) & (W Units) Table 117. China Fabrazyme (agalsidase beta) Sales by Application (2027-2032) & (W Units) Table 118. China Fabrazyme (agalsidase beta) Sales Price by Application (2021-2026) & (US$/Unit) Table 119. China Fabrazyme (agalsidase beta) Sales Price by Application (2027-2032) & (US$/Unit) Table 120. Asia Fabrazyme (agalsidase beta) Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia Fabrazyme (agalsidase beta) Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia Fabrazyme (agalsidase beta) Sales by Type (2021-2026) & (W Units) Table 123. Asia Fabrazyme (agalsidase beta) Sales by Type (2027-2032) & (W Units) Table 124. Asia Fabrazyme (agalsidase beta) Sales Price by Type (2021-2026) & (US$/Unit) Table 125. Asia Fabrazyme (agalsidase beta) Sales Price by Type (2027-2032) & (US$/Unit) Table 126. Asia Fabrazyme (agalsidase beta) Revenue by Application (2021-2026) & (US$ Million) Table 127. Asia Fabrazyme (agalsidase beta) Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Fabrazyme (agalsidase beta) Sales by Application (2021-2026) & (W Units) Table 129. Asia Fabrazyme (agalsidase beta) Sales by Application (2027-2032) & (W Units) Table 130. Asia Fabrazyme (agalsidase beta) Sales Price by Application (2021-2026) & (US$/Unit) Table 131. Asia Fabrazyme (agalsidase beta) Sales Price by Application (2027-2032) & (US$/Unit) Table 132. Asia Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 134. Asia Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 135. Asia Fabrazyme (agalsidase beta) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 136. Asia Fabrazyme (agalsidase beta) Sales by Country (2021-2026) & (W Units) Table 137. Asia Fabrazyme (agalsidase beta) Sales by Country (2027-2032) & (W Units) Table 138. Asia Fabrazyme (agalsidase beta) Sales Price by Country (2021-2026) & (US$/Unit) Table 139. Asia Fabrazyme (agalsidase beta) Sales Price by Country (2027-2032) & (US$/Unit) Table 140. Japan Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 141. South Korea Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 142. India Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 143. Australia Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 144. China Taiwan Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 145. Southeast Asia Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 146. SAMEA Fabrazyme (agalsidase beta) Revenue by Type (2021-2026) & (US$ Million) Table 147. SAMEA Fabrazyme (agalsidase beta) Revenue by Type (2027-2032) & (US$ Million) Table 148. SAMEA Fabrazyme (agalsidase beta) Sales by Type (2021-2026) & (W Units) Table 149. SAMEA Fabrazyme (agalsidase beta) Sales by Type (2027-2032) & (W Units) Table 150. SAMEA Fabrazyme (agalsidase beta) Sales Price by Type (2021-2026) & (US$/Unit) Table 151. SAMEA Fabrazyme (agalsidase beta) Sales Price by Type (2027-2032) & (US$/Unit) Table 152. SAMEA Fabrazyme (agalsidase beta) Revenue by Application (2021-2026) & (US$ Million) Table 153. SAMEA Fabrazyme (agalsidase beta) Revenue by Application (2027-2032) & (US$ Million) Table 154. SAMEA Fabrazyme (agalsidase beta) Sales by Application (2021-2026) & (W Units) Table 155. SAMEA Fabrazyme (agalsidase beta) Sales by Application (2027-2032) & (W Units) Table 156. SAMEA Fabrazyme (agalsidase beta) Sales Price by Application (2021-2026) & (US$/Unit) Table 157. SAMEA Fabrazyme (agalsidase beta) Sales Price by Application (2027-2032) & (US$/Unit) Table 158. SAMEA Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. SAMEA Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. SAMEA Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. SAMEA Fabrazyme (agalsidase beta) Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 162. SAMEA Fabrazyme (agalsidase beta) Sales by Country (2021-2026) & (W Units) Table 163. SAMEA Fabrazyme (agalsidase beta) Sales by Country (2027-2032) & (W Units) Table 164. SAMEA Fabrazyme (agalsidase beta) Sales Price by Country (2021-2026) & (US$/Unit) Table 165. SAMEA Fabrazyme (agalsidase beta) Sales Price by Country (2027-2032) & (US$/Unit) Table 166. Brazil Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 167. Argentina Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 168. Chile Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 169. Colombia Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 170. Peru Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 171. Saudi Arabia Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 172. Israel Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 173. UAE Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 174. Turkey Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 175. Iran Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 176. Egypt Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Fabrazyme (agalsidase beta) Distributors List Table 180. Fabrazyme (agalsidase beta) Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Fabrazyme (agalsidase beta) Image Figure 2. Global Fabrazyme (agalsidase beta) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fabrazyme (agalsidase beta) Market Size Share 2021 VS 2025 VS 2032 Figure 4. 5mg/vial Image Figure 5. 35mg/vial Image Figure 6. Global Fabrazyme (agalsidase beta) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Fabrazyme (agalsidase beta) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Drug store Image Figure 10. Global Fabrazyme (agalsidase beta) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Fabrazyme (agalsidase beta) Revenue (2021-2032) & (US$ Million) Figure 12. Global Fabrazyme (agalsidase beta) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Fabrazyme (agalsidase beta) Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Fabrazyme (agalsidase beta) Revenue Market Share by Region (2021-2032) Figure 15. Global Fabrazyme (agalsidase beta) Sales (2021-2032) & (W Units) Figure 16. Global Fabrazyme (agalsidase beta) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 17. Global Fabrazyme (agalsidase beta) Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Fabrazyme (agalsidase beta) Sales YoY (2021-2032) & (W Units) Figure 19. Europe Fabrazyme (agalsidase beta) Sales YoY (2021-2032) & (W Units) Figure 20. China Fabrazyme (agalsidase beta) Sales YoY (2021-2032) & (W Units) Figure 21. Asia (Excluding China) Fabrazyme (agalsidase beta) Sales YoY (2021-2032) & (W Units) Figure 22. South America, Middle East and Africa Fabrazyme (agalsidase beta) Sales YoY (2021-2032) & (W Units) Figure 23. Global Fabrazyme (agalsidase beta) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Fabrazyme (agalsidase beta) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Fabrazyme (agalsidase beta) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Fabrazyme (agalsidase beta) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Fabrazyme (agalsidase beta) Revenue Market Share by Type (2021-2032) Figure 29. Global Fabrazyme (agalsidase beta) Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 30. Global Fabrazyme (agalsidase beta) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Fabrazyme (agalsidase beta) Sales Market Share by Type (2021-2032) Figure 32. Global Fabrazyme (agalsidase beta) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Fabrazyme (agalsidase beta) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Fabrazyme (agalsidase beta) Revenue Market Share by Application (2021-2032) Figure 35. Global Fabrazyme (agalsidase beta) Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 36. Global Fabrazyme (agalsidase beta) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Fabrazyme (agalsidase beta) Sales Market Share by Application (2021-2032) Figure 38. North America Fabrazyme (agalsidase beta) Revenue Share by Type (2021-2032) Figure 39. North America Fabrazyme (agalsidase beta) Sales Share by Type (2021-2032) Figure 40. North America Fabrazyme (agalsidase beta) Revenue Share by Application (2021-2032) Figure 41. North America Fabrazyme (agalsidase beta) Sales Share by Application (2021-2032) Figure 42. North America Fabrazyme (agalsidase beta) Revenue Share by Country (2021-2032) Figure 43. North America Fabrazyme (agalsidase beta) Sales Share by Country (2021-2032) Figure 44. Europe Fabrazyme (agalsidase beta) Revenue Share by Type (2021-2032) Figure 45. Europe Fabrazyme (agalsidase beta) Sales Share by Type (2021-2032) Figure 46. Europe Fabrazyme (agalsidase beta) Revenue Share by Application (2021-2032) Figure 47. Europe Fabrazyme (agalsidase beta) Sales Share by Application (2021-2032) Figure 48. Europe Fabrazyme (agalsidase beta) Revenue Share by Country (2021-2032) Figure 49. Europe Fabrazyme (agalsidase beta) Sales Share by Country (2021-2032) Figure 50. China Fabrazyme (agalsidase beta) Revenue Share by Type (2021-2032) Figure 51. China Fabrazyme (agalsidase beta) Sales Share by Type (2021-2032) Figure 52. China Fabrazyme (agalsidase beta) Revenue Share by Application (2021-2032) Figure 53. China Fabrazyme (agalsidase beta) Sales Share by Application (2021-2032) Figure 54. Asia Fabrazyme (agalsidase beta) Revenue Share by Type (2021-2032) Figure 55. Asia Fabrazyme (agalsidase beta) Sales Share by Type (2021-2032) Figure 56. Asia Fabrazyme (agalsidase beta) Revenue Share by Application (2021-2032) Figure 57. Asia Fabrazyme (agalsidase beta) Sales Share by Application (2021-2032) Figure 58. Asia Fabrazyme (agalsidase beta) Revenue Share by Country (2021-2032) Figure 59. Asia Fabrazyme (agalsidase beta) Sales Share by Country (2021-2032) Figure 60. SAMEA Fabrazyme (agalsidase beta) Revenue Share by Type (2021-2032) Figure 61. SAMEA Fabrazyme (agalsidase beta) Sales Share by Type (2021-2032) Figure 62. SAMEA Fabrazyme (agalsidase beta) Revenue Share by Application (2021-2032) Figure 63. SAMEA Fabrazyme (agalsidase beta) Sales Share by Application (2021-2032) Figure 64. SAMEA Fabrazyme (agalsidase beta) Revenue Share by Country (2021-2032) Figure 65. SAMEA Fabrazyme (agalsidase beta) Sales Share by Country (2021-2032) Figure 66. Fabrazyme (agalsidase beta) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Fabrazyme (agalsidase beta) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 5mg/vial
  • 35mg/vial
Applications
  • Hospital
  • Drug store
Companies covered
  • Genzyme Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Fabrazyme (agalsidase beta) Market by Type
  3. 1.2.1 Global Fabrazyme (agalsidase beta) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 5mg/vial
  5. 1.2.3 35mg/vial
  6. 1.3 Fabrazyme (agalsidase beta) Market by Application
  7. 1.3.1 Global Fabrazyme (agalsidase beta) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Drug store
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Fabrazyme (agalsidase beta) Market Dynamics
  1. 2.1 Fabrazyme (agalsidase beta) Industry Trends
  2. 2.2 Fabrazyme (agalsidase beta) Industry Drivers
  3. 2.3 Fabrazyme (agalsidase beta) Industry Opportunities and Challenges
  4. 2.4 Fabrazyme (agalsidase beta) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Fabrazyme (agalsidase beta) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Fabrazyme (agalsidase beta) Revenue by Region
  3. 3.2.1 Global Fabrazyme (agalsidase beta) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Fabrazyme (agalsidase beta) Revenue by Region (2021-2026)
  5. 3.2.3 Global Fabrazyme (agalsidase beta) Revenue by Region (2027-2032)
  6. 3.2.4 Global Fabrazyme (agalsidase beta) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Fabrazyme (agalsidase beta) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Fabrazyme (agalsidase beta) Sales by Region
  9. 3.4.1 Global Fabrazyme (agalsidase beta) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Fabrazyme (agalsidase beta) Sales by Region (2021-2026)
  11. 3.4.3 Global Fabrazyme (agalsidase beta) Sales by Region (2027-2032)
  12. 3.4.4 Global Fabrazyme (agalsidase beta) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Fabrazyme (agalsidase beta) Revenue by Manufacturers
  2. 4.1.1 Global Fabrazyme (agalsidase beta) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Fabrazyme (agalsidase beta) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Fabrazyme (agalsidase beta) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Fabrazyme (agalsidase beta) Sales by Manufacturers
  6. 4.2.1 Global Fabrazyme (agalsidase beta) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Fabrazyme (agalsidase beta) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Fabrazyme (agalsidase beta) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Fabrazyme (agalsidase beta) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Fabrazyme (agalsidase beta) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Fabrazyme (agalsidase beta) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Fabrazyme (agalsidase beta) Manufacturers, Product Type & Application
  13. 4.7 Global Fabrazyme (agalsidase beta) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Fabrazyme (agalsidase beta) Market CR5 and HHI
  16. 4.8.2 2025 Fabrazyme (agalsidase beta) Tier 1, Tier 2, and Tier 3
5 Fabrazyme (agalsidase beta) Market by Type
  1. 5.1 Global Fabrazyme (agalsidase beta) Revenue by Type
  2. 5.1.1 Global Fabrazyme (agalsidase beta) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Fabrazyme (agalsidase beta) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Fabrazyme (agalsidase beta) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Fabrazyme (agalsidase beta) Sales by Type
  6. 5.2.1 Global Fabrazyme (agalsidase beta) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Fabrazyme (agalsidase beta) Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Fabrazyme (agalsidase beta) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Fabrazyme (agalsidase beta) Price by Type
6 Fabrazyme (agalsidase beta) Market by Application
  1. 6.1 Global Fabrazyme (agalsidase beta) Revenue by Application
  2. 6.1.1 Global Fabrazyme (agalsidase beta) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Fabrazyme (agalsidase beta) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Fabrazyme (agalsidase beta) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Fabrazyme (agalsidase beta) Sales by Application
  6. 6.2.1 Global Fabrazyme (agalsidase beta) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Fabrazyme (agalsidase beta) Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Fabrazyme (agalsidase beta) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Fabrazyme (agalsidase beta) Price by Application
7 Company Profiles
  1. 7.1 Genzyme Corporation
  2. 7.1.1 Genzyme Corporation Company Information
  3. 7.1.2 Genzyme Corporation Business Overview
  4. 7.1.3 Genzyme Corporation Fabrazyme (agalsidase beta) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Genzyme Corporation Fabrazyme (agalsidase beta) Product Portfolio
  6. 7.1.5 Genzyme Corporation Recent Developments
8 North America
  1. 8.1 North America Fabrazyme (agalsidase beta) Market Size by Type
  2. 8.1.1 North America Fabrazyme (agalsidase beta) Revenue by Type (2021-2032)
  3. 8.1.2 North America Fabrazyme (agalsidase beta) Sales by Type (2021-2032)
  4. 8.1.3 North America Fabrazyme (agalsidase beta) Price by Type (2021-2032)
  5. 8.2 North America Fabrazyme (agalsidase beta) Market Size by Application
  6. 8.2.1 North America Fabrazyme (agalsidase beta) Revenue by Application (2021-2032)
  7. 8.2.2 North America Fabrazyme (agalsidase beta) Sales by Application (2021-2032)
  8. 8.2.3 North America Fabrazyme (agalsidase beta) Price by Application (2021-2032)
  9. 8.3 North America Fabrazyme (agalsidase beta) Market Size by Country
  10. 8.3.1 North America Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Fabrazyme (agalsidase beta) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Fabrazyme (agalsidase beta) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Fabrazyme (agalsidase beta) Market Size by Type
  2. 9.1.1 Europe Fabrazyme (agalsidase beta) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Fabrazyme (agalsidase beta) Sales by Type (2021-2032)
  4. 9.1.3 Europe Fabrazyme (agalsidase beta) Price by Type (2021-2032)
  5. 9.2 Europe Fabrazyme (agalsidase beta) Market Size by Application
  6. 9.2.1 Europe Fabrazyme (agalsidase beta) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Fabrazyme (agalsidase beta) Sales by Application (2021-2032)
  8. 9.2.3 Europe Fabrazyme (agalsidase beta) Price by Application (2021-2032)
  9. 9.3 Europe Fabrazyme (agalsidase beta) Market Size by Country
  10. 9.3.1 Europe Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Fabrazyme (agalsidase beta) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Fabrazyme (agalsidase beta) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Fabrazyme (agalsidase beta) Market Size by Type
  2. 10.1.1 China Fabrazyme (agalsidase beta) Revenue by Type (2021-2032)
  3. 10.1.2 China Fabrazyme (agalsidase beta) Sales by Type (2021-2032)
  4. 10.1.3 China Fabrazyme (agalsidase beta) Price by Type (2021-2032)
  5. 10.2 China Fabrazyme (agalsidase beta) Market Size by Application
  6. 10.2.1 China Fabrazyme (agalsidase beta) Revenue by Application (2021-2032)
  7. 10.2.2 China Fabrazyme (agalsidase beta) Sales by Application (2021-2032)
  8. 10.2.3 China Fabrazyme (agalsidase beta) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Fabrazyme (agalsidase beta) Market Size by Type
  2. 11.1.1 Asia Fabrazyme (agalsidase beta) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Fabrazyme (agalsidase beta) Sales by Type (2021-2032)
  4. 11.1.3 Asia Fabrazyme (agalsidase beta) Price by Type (2021-2032)
  5. 11.2 Asia Fabrazyme (agalsidase beta) Market Size by Application
  6. 11.2.1 Asia Fabrazyme (agalsidase beta) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Fabrazyme (agalsidase beta) Sales by Application (2021-2032)
  8. 11.2.3 Asia Fabrazyme (agalsidase beta) Price by Application (2021-2032)
  9. 11.3 Asia Fabrazyme (agalsidase beta) Market Size by Country
  10. 11.3.1 Asia Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Fabrazyme (agalsidase beta) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Fabrazyme (agalsidase beta) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Fabrazyme (agalsidase beta) Market Size by Type
  2. 12.1.1 SAMEA Fabrazyme (agalsidase beta) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Fabrazyme (agalsidase beta) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Fabrazyme (agalsidase beta) Price by Type (2021-2032)
  5. 12.2 SAMEA Fabrazyme (agalsidase beta) Market Size by Application
  6. 12.2.1 SAMEA Fabrazyme (agalsidase beta) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Fabrazyme (agalsidase beta) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Fabrazyme (agalsidase beta) Price by Application (2021-2032)
  9. 12.3 SAMEA Fabrazyme (agalsidase beta) Market Size by Country
  10. 12.3.1 SAMEA Fabrazyme (agalsidase beta) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Fabrazyme (agalsidase beta) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Fabrazyme (agalsidase beta) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Fabrazyme (agalsidase beta) Value Chain Analysis
  2. 13.1.1 Fabrazyme (agalsidase beta) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Fabrazyme (agalsidase beta) Production Mode & Process
  6. 13.2 Fabrazyme (agalsidase beta) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Fabrazyme (agalsidase beta) Distributors
  9. 13.2.3 Fabrazyme (agalsidase beta) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst